Background Strain and the Differential Susceptibility of Podocyte-Specific Deletion of Myh9 on Murine Models of Experimental Glomerulosclerosis and HIV Nephropathy

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Johnstone, Duncan B ^a   Ikizler, Omer ^b   Zhang, Jidong ^b   Holzman, Lawrence B ^b,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PUROMYCIN; SHEEP NEPHROTOXIC SERUM; TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE MODEL; DISEASE PREDISPOSITION; DISEASE RESISTANCE; FVB N MOUSE; GENE; GENE DELETION; GLOMERULOSCLEROSIS; HIV ASSOCIATED NEPHROPATHY; KIDNEY DISEASE; MOUSE; MOUSE STRAIN; MYH9 GENE; NONHUMAN; PODOCYTE; STRAIN DIFFERENCE;

AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HIV-1; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, TRANSGENIC; NONMUSCLE MYOSIN TYPE IIA; ORGAN SPECIFICITY; PODOCYTES;

MURINAE; MUS; OVIS ARIES;

EID: 84880019397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067839     Document Type: Article

References (43)

1. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, et al. (2003) MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82: 203-215.
2. Singh N, Nainani N, Arora P, Venuto RC, (2009) CKD in MYH9-related disorders. Am J Kidney Dis 54: 732-740.
3. Johnstone DB, Zhang J, George B, Leon C, Gachet C, et al. (2011) Podocyte-Specific Deletion of Myh9 Encoding Nonmuscle Myosin Heavy Chain 2A Predisposes Mice to Glomerulopathy. Mol Cell Biol 31: 2162-2170.
4. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, et al. (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175-1184.
5. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, et al. (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192.
6. Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, et al. (2010) African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 19: 1816-1827.
7. Nelson GW, Freedman BI, Bowden DW, Langefeld CD, An P, et al. (2010) Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 19: 1805-1815.
8. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, et al. (2010) Association of Trypanolytic ApoL1 Variants with Kidney Disease in African-Americans. Science.
9. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, et al. (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet.
10. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, et al. (2010) The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21: 1422-1426.
11. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, et al. (2011) MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 155: 386-394.
12. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Hellwege JN, et al. (2012) Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 27: 1505-1511.
13. O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, Kottgen A, et al. (2011) The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 20: 2450-2456.
14. Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, et al. (2011) APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22: 1991-1996.
15. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, et al. (2012) Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13: 232-238.
16. Freedman BI, Edberg JC, Comeau ME, Murea M, Bowden DW, et al. (2010) The Non-Muscle Myosin Heavy Chain 9 Gene (MYH9) Is Not Associated with Lupus Nephritis in African Americans. Am J Nephrol 32: 66-72.
17. Conti MA, Even-Ram S, Liu C, Yamada KM, Adelstein RS, (2004) Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice. J Biol Chem 279: 41263-41266.
18. Conti MA, Adelstein RS, (2008) Nonmuscle myosin II moves in new directions. J Cell Sci 121: 11-18.
19. Zhang Y, Conti MA, Malide D, Dong F, Wang A, et al. (2012) Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood 119: 238-250.
20. Papeta N, Zheng Z, Schon EA, Brosel S, Altintas MM, et al. (2010) Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. J Clin Invest 120: 4055-4064.
21. Papeta N, Chan KT, Prakash S, Martino J, Kiryluk K, et al. (2009) Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest 119: 1178-1188.
22. Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, et al. (2010) Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 120: 1084-1096.
23. Baleato RM, Guthrie PL, Gubler MC, Ashman LK, Roselli S, (2008) Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol 173: 927-937.
24. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, et al. (1992) Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 89: 1577-1581.
25. Wyatt CM, Meliambro K, Klotman PE, (2012) Recent progress in HIV-associated nephropathy. Annu Rev Med 63: 147-159.
26. Gharavi AG, Ahmad T, Wong RD, Hooshyar R, Vaughn J, et al. (2004) Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci U S A 101: 2488-2493.
27. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV, (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203: 789-797.
28. Lin F, Emancipator SN, Salant DJ, Medof ME, (2002) Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest 82: 563-569.
29. Lin F, Salant DJ, Meyerson H, Emancipator S, Morgan BP, et al. (2004) Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol 172: 2636-2642.
30. Yanagita M, Ishimoto Y, Arai H, Nagai K, Ito T, et al. (2002) Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 110: 239-246.
31. Shinozaki M, Hirahashi J, Lebedeva T, Liew FY, Salant DJ, et al. (2002) IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest 109: 951-960.
32. Klein J, Gonzalez J, Decramer S, Bandin F, Neau E, et al. (2010) Blockade of the kinin B1 receptor ameloriates glomerulonephritis. J Am Soc Nephrol 21: 1157-1164.
33. Wang L, Fields TA, Pazmino K, Dai Q, Burchette JL, et al. (2005) Activation of Galpha q-coupled signaling pathways in glomerular podocytes promotes renal injury. J Am Soc Nephrol 16: 3611-3622.
34. Machuca E, Benoit G, Antignac C, (2009) Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. Hum Mol Genet 18: R185-194.
35. Higashi AY, Ikawa T, Muramatsu M, Economides AN, Niwa A, et al. (2009) Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2. J Immunol 182: 5633-5640.
36. Lee JY, Ristow M, Lin X, White MF, Magnuson MA, et al. (2006) RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 281: 2649-2653.
37. Nadershahi A, Fahrenkrug SC, Ellis LB, (2004) Comparison of computational methods for identifying translation initiation sites in EST data. BMC Bioinformatics 5: 14.
38. Salamov AA, Nishikawa T, Swindells MB, (1998) Assessing protein coding region integrity in cDNA sequencing projects. Bioinformatics 14: 384-390.
39. Verhey KJ, Meyer D, Deehan R, Blenis J, Schnapp BJ, et al. (2001) Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol 152: 959-970.
40. Jacobelli J, Friedman RS, Conti MA, Lennon-Dumenil AM, Piel M, et al. (2010) Confinement-optimized three-dimensional T cell amoeboid motility is modulated via myosin IIA-regulated adhesions. Nat Immunol 11: 953-961.
41. Matsushita T, Hayashi H, Kunishima S, Hayashi M, Ikejiri M, et al. (2004) Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun 325: 1163-1171.
42. Mhatre AN, Li Y, Bhatia N, Wang KH, Atkin G, et al. (2007) Generation and characterization of mice with Myh9 deficiency. Neuromolecular Med 9: 205-215.
43. Duner F, Lindstrom K, Hultenby K, Hulkko J, Patrakka J, et al. (2010) Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis. Nephron Exp Nephrol 116: e42-52.